Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients

Arthritis Care and Research

Volumn 71, Issue 8, 2019, Pages 1004-1018

  Xie, Fenglong ^a   Yun, Huifeng ^a   Levitan, Emily B ^a   Muntner, Paul ^a   Curtis, Jeffrey R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG FATALITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; COMPARATIVE STUDY; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; UNITED STATES;

EID: 85069920453     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23737     Document Type: Article

References (28)

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.
2. Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
3. Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med 2016;164:523–31.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.
5. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767–72.
6. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond) 2005;108:205–13.
7. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:518–31.
8. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al, for the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817–29.
9. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31:451–6.
10. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 2013;229:174–81.
11. Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1806–12.
12. Giles JT, Sattar N, Gabriel SE, Ridker PM, Gay S, Warne C, et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial [abstract]. Arthritis Rheumatol 2016;68 Suppl 10. URL: https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/.
13. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol 2017;69:1154–64.
14. Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813–8.
15. Xie F, Colantonio LD, Curtis JR, Kilgore ML, Levitan EB, Monda KL, et al. Development of algorithms for identifying fatal cardiovascular disease in Medicare claims. Pharmacoepidemiol Drug Saf 2018;27:740–50.
16. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402–11.
17. Curtis JR, Xie F, Chen R, Chen L, Kilgore ML, Lewis JD, et al. Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. Pharmacoepidemiol Drug Saf 2013;22:1214–21.
18. Fan AL, Fenske JN, Harrison RV, Jackson EA, Marcelino MA. Screening and management of lipids. Lipid Therapy Guideline. 2014. URL: http://www.med.umich.edu/1info/FHP/practiceguides/lipids/lipidsupdate.pdf.
19. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99–104.
20. Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: REasons for Geographic And Racial Differences in Stroke (REGARDS) Study linked with Medicare claims. Circ Cardiovasc Qual Outcomes 2014;7:611–9.
21. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291–303.
22. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012;64:1794–803.
23. Curtis JR, Xie F, Chen L, Saag KG, Yun H, Muntner P. Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 2018;77:386–92.
24. Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, et al. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 2014;66:1790–8.
25. Lin D, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993;80:557–72.
26. Lee EW, Wei LJ, Amato D. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Survival analysis: state of the art. Dordrecht: Springer; 1992: p. 237–47.
27. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.
28. U.S. Department of Health and Human Services Administration on Aging and Administration for Community Living. A profile of older americans: 2013. URL: https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2013_Profile.pdf.